Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 5 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total

P 1 (1)

P 2 (2)

Trial Status

Unknown3

Withdrawn1

Recruiting1

Clinical Trials (5)

Showing 5 of 5 trials

NCT03740893Phase 2Recruiting

PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer

NCT04895046Phase 2WithdrawnPrimary

Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma

NCT05069818Unknown

Variance of HRD From Paired Ovarian Cancer

NCT05044091Unknown

Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients

NCT03415659Phase 1Unknown

Phase I Clinical Study of HWH340 Tablet in Patients With Advanced Solid Tumors

Showing all 5 trials